71 papers found
Refreshing results…
Abstract B7: Use of ponatinib to restrict growth of non-small cell lung cancer (NSCLC) cells overexpressing FGFR1
Cyclin E1 is a common target of BMI1 and MYCN and a prognostic marker for neuroblastoma progression
Supplementary Material
Src activation plays an important key role in lymphomagenesis induced by FGFR1-fusion kinases
Constitutive Notch pathway activation in murine ZMYM2-FGFR1–induced T-cell lymphomas associated with atypical myeloproliferative disease
A) Scheme showing the metabolic pathways leading to the synthesis of both CER and S1P, two bioactive sphingolipids known for exerting opposite effects on proliferation
A) RO415253 (RO) (left) and ER50891 (ER) (right) rescued T47D cells from RA-induced growth-inhibition
A) Lack of endogenous RARα signaling (left) is demonstrated by lack of RA-induced transcription of the RARα target (right)
A) Differential response to RA according to the integrity of the RARα signaling
A) LXC5 and DNC8 cells were xenografted in nude mice, which were treated with RA according to the experimental scheme
A) Downregulation of SK1 activity (S1P spots in the upper insert) in response to RA occurs in LXC5 cells but not DNC8 cells
A) Transient exogenous expression of SK1 in DNC8 cells leads to upregulation of cyclin D1 transcription relative to cells expressing the cognate empty vector (left)
Isolation and Characterization of a Population of Stem-like Progenitor Cells From an Atypical Meningioma
Involvement of a B1 Progenitor In a Murine Model of BCR-FGFR1 Induced Leukemogenesis.
Abstract LB-93: The epigenetic basis of the tumorigenic action of retinoic acid
Abstract LB-155: Molecular targeted therapy of stem cell leukemia-lymphoma induced by ZNF198-FGFR1
Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198–fibroblast growth factor receptor-1 chimeric tyrosine kinase
Supplementary Material 1
Figure S3
Supplementary Material 3
Missing publications? Read more about our data sources.